Canadian generic pharmaceuticals company Mint Pharmaceuticals Inc announced on Thursday that it has agreed a new distribution partnership with Bayer Canada, a subsidiary of German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY).
The agreement covers the distribution of ADALAT XL (nifedipine extended-release) 30 mg tablets in Canada. First authorised in the Canadian market in 1995, the drug is indicated for the management of chronic stable angina and the management of mild to moderate essential hypertension.
Through the collaboration, Mint Pharmaceuticals and Bayer Canada aim to enhance the accessibility and availability of ADALAT XL to healthcare providers and patients across Canada.
Jaiveer Singh, CEO of Mint Pharmaceuticals, said: "With a best-in-class supply chain built over the past 15 years, Mint is proud to bring that strength to the distribution of ADALAT XL, ensuring Canadians have seamless access to this trusted therapy."
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment